Lexotan

Bromazepam, the active ingredient in Lexotan, is a benzodiazepine presented as an oral dosage form for oral use. It is prescribed for the short‑term relief of anxiety symptoms in adult patients. It acts by enhancing the inhibitory neurotransmitter GABA, leading to a calming effect on the central nervous system.

GNH USA supplies Lexotan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams of health‑care institutions worldwide, with a focus on quality assurance and regulatory compliance.

Bromazepam is used to manage anxiety‑related conditions by modulating central nervous system activity. - Anxiety disorders: reduces excessive worry and tension in patients with generalized or situational anxiety. - Acute anxiety episodes: provides rapid, short‑term symptom relief during periods of heightened stress. - Pre‑operative anxiety: helps calm patients before surgical or diagnostic procedures. - Panic disorder: diminishes frequency and intensity of sudden panic attacks. - Adjustment disorder with anxiety: eases emotional distress associated with life changes.

Bromazepam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness: feeling of sleepiness or reduced alertness. - Fatigue: general lack of energy or tiredness. - Dizziness: sensation of light‑headedness or unsteadiness. - Impaired coordination: reduced motor control and clumsiness. - Headache: mild to moderate head pain. - Nausea: feeling of stomach upset.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing, especially with other depressants. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Dependence and withdrawal: risk of physical dependence with prolonged use, leading to withdrawal symptoms upon abrupt cessation. - Psychomotor impairment: severe confusion or agitation. - Memory impairment: difficulty forming new memories.

When prescribing bromazepam, several precautions should be observed to ensure safe use. - Pregnancy: Category D – avoid use unless benefits outweigh potential fetal risks. - Elderly patients: increased sensitivity – start with the lowest effective dose and monitor closely. - Concomitant alcohol: may intensify sedation and respiratory depression; avoid alcohol consumption. - Operating machinery: potential drowsiness can impair driving or use of hazardous equipment. - Dependence risk: prolonged therapy can lead to tolerance and physical dependence; limit duration as appropriate. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Bromazepam can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid): - Other central nervous system depressants (e.g., opioids, barbiturates): additive sedation and risk of respiratory depression. - Alcohol: potentiates sedative effects, increasing drowsiness and impairment.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., SSRIs, SNRIs): may enhance central nervous system depression. - Antihistamines (e.g., diphenhydramine): can increase drowsiness. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise bromazepam plasma concentrations. - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce bromazepam effectiveness.